Topic is suspended
Status Suspended
Process TAG
ID number 805


Key events during the development of the guidance:

Date Update
15 December 2020 Suspended. Topic is suspended
15 December 2020 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Rigosertib for treating higher risk myelodysplastic syndromes following treatment with hypomethylating agents. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance